Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05168930 | Zanubrutinib and Venetoclax in CLL (ZANU-VEN) | PHASE2 | RECRUITING | 45 | — | — | Feb 18, 2022 | Oct 28, 2028 | Dec 5, 2025 | 4 | United States |
Assessed by flow cytometry (FC)
| Arm | Type | Description |
|---|---|---|
| Cohort A: BTKi and BCL2i naive | EXPERIMENTAL | Participants who have never received a BTK inhibitor or a BCL-2 inhibitor |
| Cohort B: BTKi or BCL2i exposed without disease progression | EXPERIMENTAL | Participants who have received prior treatment with a BTK or BCL-2 inhibitor and discontinued treatment for any reason other than disease progression |
| Cohort C: BTKi exposed and with disease progression | EXPERIMENTAL | Participants who experienced disease progression on a prior BTK inhibitor. Participants with BTK C481X mutation at enrollment will be excluded. |
| Name | Type | Description |
|---|---|---|
| Venetoclax | DRUG | C4-15 |
| Zanubrutinib | DRUG | C1-15 |
Inclusion Criteria * Confirmed diagnosis of CLL or SLL as per 2018 International Workshop on CLL (IWCLL) criteria. * Participants must have relapsed after at least one prior line of therapy and must currently require therapy by 2019 IWCLL criteria. * For enrollment to Cohort A: Participants must be...